Shikari® (S-ATD) Anti-Denosumab ELISA w/confirmation
DEN-QNS-PRO
Enzyme immunoassay for the quantitative determination of antibodies to denosumab (Prolia®) in serum and plasma with confirmation.
This kit has been especially developed for the quantitative antibodies to denosumab in serum and plasma samples.
Denosumab (Prolia®) was associated to the development of anti-denosumab antibodies, even some were reported to be neutralizing, in various percentages of patients during therapy with the drug Prolia®. This might lead to severe complications. This kit can be efficiently used for monitoring anti-Denosuman antibodies during therapy and offers the clinician a tool for decision on possible preventive measures such as possible addition of immunosuppressive drug to reduce anti-Denosumab antibodies..
All SHIKARI® ELISA kits are suitable for biosimilar work.
All SHIKARI® ELISA kits are produced under ISO 13485 quality system.
Research Use Only (RUO)
For technical inquiry, IFU and other relevant documents please contact techsupport@matriksbiotek.com
| Required Volume (µl) | 5 |
| Total Time (min) | 140 |
| Sample | Serum, plasma |
| Sample Number | 96 |
| Detection Limit (ng/mL) | 18,75 |
| Spike Recovery (%) | Between 85-115 |
| Shelf Life (year) | 1 |
| Assay type | Quantitative |
| Species Reactivity | Human |
| Storage conditions | Store at +4°C. Please refer to protocols. |
| Shipping conditions | At room temperature |
| # | File | Action |
|---|---|---|
| Safety Data Sheet (SDS) | Download |
Publications with this drug
| # | File | Action |
|---|---|---|
| Nanoparticle and Macromolecular Transfer across the Human Placental Barrier | Download | |
| Rahman, Mohammed Tanjimur, et al. "Nanoparticle-mediated synergistic drug combination for treating bone metastasis." Journal of Controlled Release 357 (2023): 498-510. | Visit Link | |
| Peterlin, Anton AN, et al. "Rethinking Bacterial Osteolysis: Translational Evidence From a Porcine Model and Fracture‐Related Infections." APMIS 134.2 (2026): e70151. | Visit Link |
